Alivus Life Sciences Q2 FY27: revenue up 16.0% to ₹6,820 Mn, PAT up 51.3% as margins expand
Q2 FY27 revenue up 16.0% YoY to ₹6,820 Mn, EBITDA up 47.0% at 41.8% margin, PAT up 51.3% to ₹1,968 Mn.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- ₹6,820 Mn, up 16.0% YoY and 6.5% QoQ
- EBITDA
- ₹2,851 Mn with margin at 41.8%
- PAT
- ₹1,968 Mn, up 51.3%
- Period
- Q2 FY27
- Positioning
- Alivus presents itself as a generic API and CDMO maker, 92% Generic API and 8% CDMO in Q2FY27, with 79% of revenue from non-GPL customers across Europe, Japan, North America, LATAM and ROW.
📈 Q2 FY27 revenue from operations was ₹6,820 Mn, up 16.0% YoY and 6.5% QoQ; EBITDA rose 47.0% YoY to ₹2,851 Mn with margin at 41.8%, and PAT rose 51.3% to ₹1,968 Mn. Gross margin reached 64.4%, up 670 bps YoY on product mix. H1FY27 revenue was ₹13,224 Mn and PAT ₹3,569 Mn.
📈 Non-GPL revenue grew 20.8% YoY and now makes up 79% of revenue, while GPL (Glenmark) grew only 1% on inventory rationalisation. CDMO revenue jumped 79.9% YoY to ₹500 Mn, and the company says several projects are in advanced stages of discussion.
🏭 Management states it will grow through new launches, geographic expansion, a CDMO ramp-up, complex API platforms, iron compounds and oncology/HP API. The presentation lists brownfield additions of ~160KL at Dahej (Q3 FY27) and ~100KL at Ankleshwar (Q4 FY27), plus a greenfield Solapur site, taking planned capacity to 2,690 KL by FY29E.
📌 The company points to free cash flow of ₹2,702 Mn, cash of ₹10,116 Mn, ROICE of ~34% and a 30-product HP API grid it says addresses a TAM of ~$86 bn as backing for these plans.
Also from Alivus Life Sciences
Alivus Life Sciences uploads audio recording of Q2 FY2027 earnings call held October 30, 2026
30 Oct 2026
Alivus Life Sciences Q2 FY27: EBITDA up 47.0% YoY to Rs. 2,851 Mn, EBITDA margin at record 41.8%
29 Oct 2026
Standalone results for the 30 Sep'26
29 Oct 2026
More numbers
- Revenue from operations, Q2FY276,820 (In ₹ Million)
- Revenue growth YoY, Q2FY2716.0%
- EBITDA, Q2FY272,851 (In ₹ Million)
- EBITDA margin, Q2FY2741.8%
- PAT, Q2FY271,968 (In ₹ Million)
- PAT growth YoY, Q2FY2751.3%
- Revenue from operations, H1FY2713,224 (In ₹ Million)
- PAT, H1FY273,569 (In ₹ Million)
- Gross margin, Q2FY2764.4%
- Free cash flow₹2,702 Mn
- Cash and equivalents incl. short-term investments, 30 Sep 2026₹10,116 Mn
- CDMO revenue, Q2FY27500 (Revenue In ₹ Million)
- Non-GPL revenue growth YoY, Q2FY2720.8%
- Planned total reactor capacity, FY29E (KL)2,690
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.